Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure

Patients with hepatitis C virus (HCV) who have virological failure (VF) after treatment containing a nonstructural protein 5A (NS5A) inhibitor have limited retreatment options. MAGELLAN‐1 Part 2 was a randomized, open‐label, phase 3 study to evaluate the efficacy and safety of ribavirin (RBV)‐free g...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Hepatology
Autori principali: Poordad, Fred, Pol, Stanislas, Asatryan, Armen, Buti, Maria, Shaw, David, Hézode, Christophe, Felizarta, Franco, Reindollar, Robert W., Gordon, Stuart C., Pianko, Stephen, Fried, Michael W., Bernstein, David E., Gallant, Joel, Lin, Chih‐Wei, Lei, Yang, Ng, Teresa I., Krishnan, Preethi, Kopecky‐Bromberg, Sarah, Kort, Jens, Mensa, Federico J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2018
Soggetti:
Original Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5901397/
https://ncbi.nlm.nih.gov/pubmed/29152781
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep.29671
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi